MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

Slides:

Advertisements

Similar presentations

Mouse Double Minute 2 (MDM2)

Advertisements

MAPK pathway inhibitors.

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Atg7 deficiency has distinct consequences for tumor establishment and maintenance in BrafV600E-driven lung tumors and is associated with the emergence.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

HIV Drug to Aid Melanoma Therapies?

The summary page for cancer profiles.

Activated membrane signaling promotes survival in response to radiation. Activated membrane signaling promotes survival in response to radiation. Radiation.

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

NICD1 immunohistochemical staining in normal and tumor tissue.

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Mutant BRAF Melanomas—Dependence and Resistance

TNFα is an important survival and growth signal for melanoma.

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state Immunohistochemical analysis.

TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor tissues. TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor.

Expression analysis of IGFBP-3 using human whole-genome microarray.

In vivo homing of intravenously injected CSNRDARRC peptide to bladder tumor in rats. In vivo homing of intravenously injected CSNRDARRC peptide to bladder.

Expression profile of RSPO1 and 2 in gastric cancer.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Protein expression profile in a dasatinib-resistant cell line.

IL6 mRNA is not detected in metastatic prostate cancer cells.

Oncogenic indel hotspots.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

AXL is not expressed in human prostate tumors.

Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

IL-13Rα2 expression is associated to human colon cancer progression and poor survival of patients with colorectal cancer. IL-13Rα2 expression is associated.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

Expression pattern of TLR-4 and MyD88 in EOC cells.

Antitumor effects of celastrol in vitro and in vivo.

Immunohistochemical analysis of dUTPase in human breast adenocarcinoma

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Potential model of HMQ1611 inhibiting breast cancer cell proliferation

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Reduced klotho expression in pancreatic cancer.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

Establishment of transcriptional class distinction in melanocytes.

GATA-3 immunostaining was scored semiquantitatively; tumors with

The critical roles of miR-23a and miR-27a in colorectal cancer progression. miR-23a primarily increases cell motility through downregulation of its target.

Progastrin staining in colon adenomas and adenocarcinomas.

Histology (H&E; original magnification, ×100 for B-2P/C-12P/C-64P and ×40 for C-10P; top) of small-sized lung adenocarcinomas and immunohistochemical staining.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

Enrichment of two rare SNPs among ABC DLBCL tumors.

HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.

Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

Regulation of signaling by wild-type and oncogenic Ras.

Core melanoma escape pathways during disease progression on BRAF inhibitor therapy. Core melanoma escape pathways during disease progression on BRAF inhibitor.

EPHA2 inhibitors inhibit phosphorylation of AKT and ERK, arrest cell cycle at G0–G1, and induce apoptosis in both vemurafenib (VEM)-sensitive and VEM-resistant.

AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. A,

A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.

CD36 expression is coordinately regulated in multiple cellular compartments. CD36 expression is coordinately regulated in multiple cellular compartments.

CD36 expression in tissue adjacent and distal to the tumor.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

HER2 amplification in EGFRT790M–negative tumors with acquired resistance. HER2 amplification in EGFRT790M–negative tumors with acquired resistance. A,HER2.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Antiangiogenic effects of PI3K inhibitor NVP-BKM120.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

Epithelial and stromal percentage clusterin staining in normal nonadjacent colonic tissue and matched tumor tissue in 202 patients with stage II colorectal.

AXL is not necessary for maintenance of intrinsic resistance.

Genotype-specific combinatorial drug sensitivities in melanoma.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

GSN and DNMT1 expression are inversely correlated in a pattern associated with patient survival. GSN and DNMT1 expression are inversely correlated in a.

Presentation transcript:

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. A, transcriptional class distinction in BRAFV600-mutant melanoma tumor samples. B, examples of AXL and MITF staining in pretreatment melanoma biopsies (magnification, ×40). C, comparison of progression-free survival between MITF-positive/AXL-negative and MITF-negative/AXL-positive classes. *, P = 0.0313, two-tailed t test. David J. Konieczkowski et al. Cancer Discovery 2014;4:816-827 ©2014 by American Association for Cancer Research